We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed at $451.59 in the latest trading session, marking a -2.36% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 1.36%. At the same time, the Dow lost 1.64%, and the tech-heavy Nasdaq lost 1.46%.
Coming into today, shares of the drugmaker had lost 3.11% in the past month. In that same time, the Medical sector lost 5.66%, while the S&P 500 lost 1.76%.
The investment community will be paying close attention to the earnings performance of Vertex Pharmaceuticals in its upcoming release. The company's earnings per share (EPS) are projected to be $4.47, reflecting a 10.1% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $3.05 billion, reflecting a 10.11% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $19.19 per share and a revenue of $12.98 billion, signifying shifts of +4.29% and +8.13%, respectively, from the last year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.49% lower within the past month. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 24.1. This denotes a premium relative to the industry average Forward P/E of 18.83.
It is also worth noting that VRTX currently has a PEG ratio of 1.74. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. VRTX's industry had an average PEG ratio of 1.55 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 140, putting it in the bottom 43% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Vertex Pharmaceuticals (VRTX - Free Report) closed at $451.59 in the latest trading session, marking a -2.36% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 1.36%. At the same time, the Dow lost 1.64%, and the tech-heavy Nasdaq lost 1.46%.
Coming into today, shares of the drugmaker had lost 3.11% in the past month. In that same time, the Medical sector lost 5.66%, while the S&P 500 lost 1.76%.
The investment community will be paying close attention to the earnings performance of Vertex Pharmaceuticals in its upcoming release. The company's earnings per share (EPS) are projected to be $4.47, reflecting a 10.1% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $3.05 billion, reflecting a 10.11% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $19.19 per share and a revenue of $12.98 billion, signifying shifts of +4.29% and +8.13%, respectively, from the last year.
Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.49% lower within the past month. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Vertex Pharmaceuticals's current valuation metrics, including its Forward P/E ratio of 24.1. This denotes a premium relative to the industry average Forward P/E of 18.83.
It is also worth noting that VRTX currently has a PEG ratio of 1.74. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. VRTX's industry had an average PEG ratio of 1.55 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 140, putting it in the bottom 43% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.